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We report an epidermal growth factor receptor (EGFR) tandem kinase domain duplication (TKD-EGFR) muta-
tion in a non–small-cell lung cancer (NSCLC) patient who 
had a greater than 10-year response to EGFR tyrosine kinase 
inhibitor (TKI) therapy. The mutation was present in both the 
primary treatment–naive tumor and in metastatic biopsies 
taken approximately 20 years later. TKD-EGFR has been 
described in glioblastoma and is known to result in constitu-
tive EGFR activation. To our knowledge, this is the first report 
of the TKD-EGFR mutation in lung cancer.
CASE PRESENTATION
A 45-year-old woman with less than one pack-year 
smoking history presented in 1995 with persistent cough. 
Diagnostic work-up revealed an isolated pulmonary infil-
trate at left lower lobe, and a bronchoscopic biopsy showed 
that this was a bronchoalveolar carcinoma, nonmucinous 
type. The patient underwent a left lower lobectomy with a 
final pathologic stage of T3N0. She presented with recurrent 
cough in 1999 and was found to have extensive pulmonary 
infiltrates bilaterally, and a biopsy confirmed recurrent bron-
choalveolar carcinoma. The patient achieved disease con-
trol with cytotoxic chemotherapy, which included paclitaxel 
and capecitabine until 2003. The same year, gefitinib was 
approved by U.S. Food and Drug Administration for patients 
who failed prior chemotherapy, thus the patient began treat-
ment with gefitinib. Subsequently, she demonstrated partial 
tumor response and significant improvement in her symp-
toms (Fig. 1). The tumor response was durable with disease 
control until 2009 when she was found to have symptomatic 
and radiographic disease progression. Subsequently, she 
received chemotherapy with pemetrexed, which was discon-
tinued due to progressive disease. The patient was rechal-
lenged with erlotinib in late 2009 with which again achieved 
durable tumor response. When there was evidence of mild 
progression in 2012, the patient underwent a biopsy, and this 
was tested with a polymerase chain reaction–based assay for 
common activating EGFR mutations (L868R, L861Q, exon 
19 deletion, G719X, T790M, S768I, exon 20 insertion); 
however, none of the mutations were detected in the tumor. 
The patient continued on erlotinib until late 2014 when she 
began to demonstrate symptomatic disease progression. She 
underwent a repeat biopsy and the specimen was evaluated 
with UW-OncoPlex, a next-generation sequencing (NGS) 
platform, which confirmed the absence of common acti-
vating EGFR mutations and other known drivers including 
BRAF mutations and ALK, ROS1, and RET rearrangement.1 
However, a tandem kinase domain duplication was detected 
involving exons 18 to 25 of the EGFR gene (Fig. 2). The 
tumor also harbored EGFR p.T790M and CTNNB1 p.S37C 
mutations. Subsequently, the original surgical tumor speci-
men was evaluated by NGS, which again revealed the pres-
ence of TKD-EGFR, but no evidence of EGFR p.T790M- or 
CTNNB1 p.S37C-mutant subpopulations. The presence of 
the tandem kinase domain duplication was confirmed with 
Sanger sequencing (Fig. 2C). The patient currently contin-
ues on erlotinib and is under evaluation for clinical trial par-
ticipation of T790M TKI therapy.
DISCUSSION
We present a case of metastatic adenocarcinoma in a 
patient with minimal smoking history who demonstrated 
remarkable disease control with EGFR TKI therapy despite 
the lack of a known activating EGFR mutation on an initial 
polymerase chain reaction–based testing. Evaluation by NGS 
revealed a tandem duplication of the tyrosine kinase domain 
in the EGFR gene in the patient’s surgical specimen at initial 
diagnosis and in recently acquired metastatic tumors. To our 
knowledge, this is the first report of tandem kinase domain 
duplication in EGFR in lung cancer. TKD-EGFR has been 
reported to be present in a subset of glioblastoma multi-
forme2,3 and has been shown to result in constitutive activity of 
the EGFR gene that is ligand- and dimerization independent. 
TKD-EGFR has also been shown to promote tumor growth 
in vivo.2
Our patient’s case demonstrates her tumor’s remarkable 
dependency on EGFR signaling and thus strongly suggesting 
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that TKD-EGFR is likely the mechanism underlying the 
patient’s remarkable response to EGFR TKI therapy. The 
patient’s post-TKI biopsy also demonstrated a low level of 
T790M, which indicates that there is a small population of 
resistant clones that is developing under the selective pres-
sure of EGFR blockade. Studies of EGFR TKI in wild-type 
patients have shown that 3% to 10% of patients without a 
known activating mutation demonstrated meaningful disease 
response to an EGFR TKI.4–6 This subset of patients, as they 
are “EGFR wild type,” are unlikely to be offered an EGFR 
TKI, thus missing the opportunity to receive an effective 
treatment. Therefore, there is a need to discover additional 
markers of EGFR TKI sensitivity to maximize its benefit in 
NSCLC patients.
Here, we report TKD-EGFR as a novel EGFR abnor-
mality in NSCLC in a patient who demonstrated remarkable 
response to TKI therapy. This case illustrates the value of 
in-depth molecular testing with NGS of NSCLCs in patients 
with no or minimal smoking history.
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FIGURE 1.  Pregefitinib and post-
gefitinib computed tomography 
images; patient started gefitinib on 
July 16, 2003 (computed tomog-
raphy images: July 2003 and 
November 2004).
FIGURE 2. EGFR tandem kinase domain duplication 
(TKD-EGFR). A tandem duplication of EGFR exons 
18 to 25 was detected by targeted next-generation 
sequencing. A, Genomic position of TKD-EGFR 
mutation. B, Schematic of native EGFR protein and 
TKD-EGFR. Amino acid positions given at bottom. 
C, Sanger sequencing confirmation of genomic 
breakpoints showing fusion of intron 25 to intron 
17. Genomic breakpoints are hg19 coordinates.
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